期刊
NEUROPEDIATRICS
卷 41, 期 5, 页码 199-208出版社
GEORG THIEME VERLAG KG
DOI: 10.1055/s-0030-1269906
关键词
tuberous sclerosis; angiomyolipoma; epilepsy; lymphangioleiomyomatosis
资金
- NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000077] Funding Source: NIH RePORTER
- NCATS NIH HHS [UL1 TR000077] Funding Source: Medline
Tuberous sclerosis complex (TSC) is an important cause of epilepsy and autism, as well as renal and pulmonary disease in adults and children. Affected individuals are subject to hamartomas in various organ systems which result from constitutive activation of the protein kinase mTOR (mammalian target of rapamycin). The clinical course, prognosis and appropriate therapy for TSC patients are often different from that for individuals with epilepsy, renal tumors, or interstitial lung disease, from other causes. Additionally, TSC serves as a model for other conditions in which the mTOR pathways are also up-regulated. This article reviews the molecular pathophysiology and management of neurological, renal and pulmonary manifestations of the disorder. The use of mTOR inhibitors such as rapamycin and everolimus is discussed and recent clinical trials of these drugs in TSC are reviewed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据